Drugs / cancer stem cell vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02176746 | Jun 2014 → May 2015 | colorectal cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT02084823 | Mar → Oct 2014 | lung neoplasm | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT02115958 | Mar 2014 → May 2015 | lung neoplasm | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT02074046 | Feb 2014 → Mar 2015 | pancreatic neoplasm | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT02089919 | Feb 2014 → Feb 2015 | liver and intrahepatic bile duct neoplasm | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cancer stem cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02084823 ↗ |
| Action | Deplete | “CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro” NCT02074046 ↗ |
| Modality | Vaccine | “CSC-loaded DC vaccines” NCT02074046 ↗ |